ArticleDrug design, development and therapy2026
Lenvatinib in Combination with PD-1 Blockades as Re-Challenging Treatment for Patients with Metastatic Soft Tissue Sarcoma Following TKI Treatment Failure: A Retrospective Study.
Article in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Previous research has demonstrated the effectiveness of lenvatinib and programmed death-1 (PD-1) blockades in the treatment of sarcoma. However, there is limited information regarding the efficacy and safety of combining lenvatinib with PD-1 blockades as a re-challenge therapy in patients with metastatic soft tissue sarcoma (STS) following prior treatment failure with tyrosine kinase inhibitors (TKIs). Methods: Between October 2019 and September 2024, 28 patients with metastatic STS who received rechallenge treatment with lenvatinib in combination with PD-1 blockades following progression on prior TKI treatment were included in this retrospective analysis. The primary endpoint was progression-free survival (PFS). Secondary endpoints included objective response rate (ORR), clinical benefit rate (CBR), overall survival (OS), and safety. Results: Of the 28 patients, ORR and CBR were 0 and 64.3%, respectively. The median duration of follow-up was 26 months (range, 13.2-38.8). The median PFS was 4.8 months (95% CI: 2.7-6.9), while the median OS was 23 months (95% CI: 16.5-29.5). Approximately 96.4% of patients experienced adverse events of grade 1 or higher. Grade 3 adverse events were reported in 5 patients, accounting for 17.9%. Conclusion: Our findings indicate that patients with metastatic STS may potentially benefit from the combination of lenvatinib and PD-1 blockades following the failure of prior TKI therapy. The combination of lenvatinib and PD-1 blockade therapy showed encouraging survival results in patients with metastatic STS, with an acceptable and manageable safety profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.